Related Experiment Video

Updated: Dec 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Cervicomedullary hemangioblastoma treated with bevacizumab

Gloria Mak1, Almunder Algird2, Jeffrey Greenspoon3

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Neuro-Oncology Advances
|September 10, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
bevacizumabhemangioblastoma

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.4K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K

Related Experiment Videos

Last Updated: Dec 9, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

10.4K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

Muscle mitochondrial changes in antisynthetase syndrome and other idiopathic inflammatory myopathies.

Journal of neuropathology and experimental neurology·2025

Exploring the Utility of Virtual Clinics for Neurosurgical Patient Consults: Cohort Study to Assess Feasibility.

JMIR formative research·2025

Collision Tumor of the Clivus: Chordoma and Chronic Lymphocytic Leukemia.

Journal of neurological surgery. Part A, Central European neurosurgery·2025

Incidence of Venous Thromboembolism in Newly Diagnosed Glioblastoma and Associated Risk Factors: A Retrospective Chart Review.

Current oncology (Toronto, Ont.)·2025

Devastating neurologic consequences of localized scleroderma en coup de sabre of the scalp-2 case studies.

Journal of scleroderma and related disorders·2025

Intraventricular WHO Grade 3 Pleomorphic Xanthoastrocytoma: A Rare Case Report and Review of the Literature.

Case reports in pathology·2025

Neuronal precursor cell persistence in ganglioglioma is associated with extracellular matrix remodeling and immune cell infiltration.

Neuro-oncology advances·2026

Deep learning-based detection of pediatric brain tumor presence on MRI.

Neuro-oncology advances·2026

Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis.

Neuro-oncology advances·2026

Outcomes of target therapies for pediatric BRAF V600-mutant low-grade gliomas: A systematic review and meta-analysis.

Neuro-oncology advances·2026

Stem-like TCF1+CD8+ T cells are associated with improved survival in male glioblastoma patients.

Neuro-oncology advances·2026

Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas.

Neuro-oncology advances·2026

Development and initial clinical application of the HKL Thrombus Burden Classification for endovascular salvage of thrombosed haemodialysis access.

The journal of vascular access·2026

Clonal hematopoiesis in immune-related and neurological disorders.

Immunological medicine·2026

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).

British journal of haematology·2026

Recurrent Postpartum Atypical Hemolytic Uremic Syndrome Caused by a C3 Pathogenic Variant: A Case Report.

International journal of women's health·2026

Point-of-care assessment of complement activation in the ICU: a feasibility study of rapid terminal complement complex detection in critical illness.

Frontiers in immunology·2026

Utility of TcPO2 in Assessing Microcirculatory Improvement and Minimizing Amputation Levels for Hemodialysis Access-Induced Distal Ischemia: A Case Report.

Yonago acta medica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us